《中国期刊全文数据库》收录期刊
《中国核心期刊（遴选）数据库》收录期刊
《中文科技期刊数据库》收录期刊
Surgical Research and New Technique

Surgical Research and New Technique >

2023 , Vol. 12 >Issue 1: 1 - 5

DOI: https://doi.org/10.3969/j.issn.2095-378X.2023.01.001

Commentary

Ten-year review and prospect of transanal total mesorectal excision for rectal cancer

  • WEI Pengyu ,
  • LI Yang ,
  • GAO Jiale ,
  • YAO Hongwei ,
  • ZHANG Zhongtao
Expand
  • Department of General Surgery, Beijing Friendship Hospital of Capital Medical University, National Clinical Research Center for Digestive Diseases, Clinical Practice and Research Center for Colorectal Neoplasm of Capital Medical University, Beijing 100050, China

Received date: 2023-02-23

  Online published: 2023-05-26

Fold

Abstract

Rectal cancer is one of the most common malignant tumors of the gastrointestinal tract. Surgery-centered multidisciplinary therapy is still the main strategy for the treatment of rectal cancer. In China, low-to-mid rectal cancer accounts for the majority. In recent years, transanal total mesorectal excision (taTME) has become a hot area of surgery for low-to-mid rectal cancer. Since it was first reported in 2010, taTME has undergone about 10 years of development, and a standardized theoretical and practical system has been gradually formed as a result of the continuous technical progress of this procedure. Meanwhile, the continuous advancement of domestic and international research and the iterative launch of expert consensus and guidelines have provided scientific evidence for the safety and efficacy of this procedure. In the future, it is expected that research centers in China will carry out more extensive structured training and clinical trials to obtain high-level evidence-based clinical research results of taTME, and form more mature clinical practice guidelines to carry out this technique in a safer and more standardized manner, in the hope of bringing benefits to more rectal cancer patients.

Key words： Rectal cancer; Transanal total mesorectal excision; Structured training; Clinical research

Cite this article

WEI Pengyu , LI Yang , GAO Jiale , YAO Hongwei , ZHANG Zhongtao . Ten-year review and prospect of transanal total mesorectal excision for rectal cancer[J]. Surgical Research and New Technique, 2023 , 12(1) : 1 -5 . DOI: 10.3969/j.issn.2095-378X.2023.01.001

References

[1] Siegel RL, Miller K D, Fuchs H E, et al.Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[2] Zheng R, Zhang S, Zeng H, et al.Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Cent, 2022, 2(1): 1-9.
[3] 姚宏伟, 李心翔, 崔龙, 等. 中国结直肠癌手术病例登记数据库2019年度报告:一项全国性登记研究[J]. 中国实用外科杂志, 2020, 40(1): 106-110.
[4] Sylla P, Rattner DW, Delgado S, et al.NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance[J]. Surg Endosc, 2010, 24(5): 1205-1210.
[5] Heald RJ, Husband EM, Ryall RD.The mesorectum in rectal cancer surgery—the clue to pelvic recurrence [J]. Br J Surg, 1982, 69(10): 613-616.
[6] Jacobs M, Verdeja JC, Goldstein HS.Minimally invasive colon resection (laparoscopic colectomy)[J]. Surg Laparosc Endosc, 1991, 1(3): 144-150.
[7] Guillou PJ, Quirke P, Thorpe H, et al.Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial[J]. Lancet, 2005, 365(9472): 1718-1726.
[8] Kang SB, Park JW, Jeong SY, et al.Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial[J]. Lancet Oncol, 2010, 11(7): 637-645.
[9] Bonjer HJ, Deijen CL, Abis GA, et al.A randomized trial of laparoscopic versus open surgery for rectal cancer[J]. N Engl J Med, 2015, 372(14): 1324-1332.
[10] Jiang WZ, Xu JM, Xing JD, et al.Short-term outcomes of laparoscopy-assisted vs open surgery for patients with low rectal cancer: the LASRE randomized clinical trial[J]. JAMA Oncol, 2022, 8(11): 1607-1615.
[11] Fleshman J, Branda M, Sargent DJ, et al.Effect of laparoscopic-assisted resection vs open resection of stage Ⅱ or Ⅲ rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial[J]. JAMA, 2015, 314(13): 1346-1355.
[12] Stevenson A R, Solomon M J, Lumley J W, et al.Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial[J]. JAMA, 2015, 314(13): 1356-1363.
[13] 陈远光, 胡明, 雷建, 等. 经肛内镜全直肠系膜切除治疗直肠癌[J]. 中国内镜杂志, 2010, 16(12): 1261-1265.
[14] 张浩, 张云生, 金雄伟, 等. 完全经肛单孔腹腔镜全直肠系膜切除术治疗直肠癌[J]. 中国内镜杂志, 2012, 18(4): 379-383.
[15] Zhang H, Zhang YS, Jin XW, et al.Transanal single-port laparoscopic total mesorectal excision in the treatment of rectal cancer[J]. Tech Coloproctol, 2013, 17(1): 117-123.
[16] TaTME Guidance Group representing the ESCP (European Society of Coloproctology), in collaboration with the ASCRS (American Society of Colon and Rectal Surgeons), ACPGBI (Association of Coloproctology of Great Britain and Ireland), ECCO (European Crohn’s and Colitis Organisation), EAES (European Association of Endoscopic Surgeons), ESSO (European Society of Surgical Oncology), CSCRS (Canadian Society of Colorectal Surgery), CNSCRS (Chinese Society of Colorectal Surgery), CSLES (Chinese Society of Laparo-Endoscopic Surgery), CSSANZ (Colorectal Surgical Society of Australia and New Zealand), JSES (Japanese Society of Endoscopic Surgery), SACP (Argentinian Society of Coloproctology), SAGES (Society of American Gastrointestinal and Endoscopic Surgeons), BSCP (Brazilian Society of Coloproctology), Swiss-MIS (Swiss Association for Minimally Invasive Surgery). International expert consensus guidance on indications, implementation and quality measures for transanal total mesorectal excision[J]. Colorectal Dis, 2020, 22(7): 749-755.
[17] Adamina M, Buchs NC, Penna M, et al.St.Gallen consensus on safe implementation of transanal total mesorectal excision[J]. Surg Endosc, 2018, 32(3): 1091-1103.
[18] 张忠涛, 郑民华, 姚宏伟, 等. 直肠癌经肛全直肠系膜切除专家共识及手术操作指南(2017版)[J]. 中国实用外科杂志, 2017, 37(9): 978-984.
[19] 姚宏伟, 张忠涛, 郑民华. 直肠癌经肛全直肠系膜切除中国专家共识及临床实践指南(2019版)[J]. 中国实用外科杂志, 2019, 39(11): 1121-1128.
[20] 姚宏伟, 陈建志, 张宏宇, 等. 中国经肛全直肠系膜切除手术病例登记协作研究数据库2018年度报告:一项全国性登记研究[J]. 中国实用外科杂志, 2019, 39(1): 85-91.
[21] Penna M, Hompes R, Arnold S, et al.Transanal total mesorectal excision: International registry results of the first 720 cases[J]. Ann Surg, 2017, 266(1): 111-117.
[22] Marks JH, Myers EA, Zeger EL, et al.Long-term outcomes by a transanal approach to total mesorectal excision for rectal cancer[J]. Surg Endosc, 2017, 31(12): 5248-5257.
[23] Yao H, An Y, Zhang H, et al.Transanal total mesorectal excision: short-term outcomes of 1283 cases from a nationwide registry in China[J]. Dis Colon Rectum, 2021, 64(2): 190-199.
[24] Larsen SG, Pfeffer F, Korner H, et al.Norwegian moratorium on transanal total mesorectal excision[J]. Br J Surg, 2019, 106(9): 1120-1121.
[25] Deijen CL, Velthuis S, Tsai A, et al.COLOR Ⅲ: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer[J]. Surg Endosc, 2016, 30(8): 3210-3215.
[26] Lelong B, DE Chaisemartin C, Meillat H, et al.A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design[J]. BMC Cancer, 2017, 17(1): 253.
Options
Outlines

/

〈 〉